Biosite Triage BNP Reduces Diagnosis Uncertainty To 11%, NEJM Study Finds
This article was originally published in The Gray Sheet
Executive Summary
Biosite plans to file a 510(k) application in mid-2003 seeking a therapeutic monitoring indication for its Triage B-type natriuretic peptide (BNP) test to aid in diagnosis of congestive heart failure
You may also be interested in...
Biosite Aims For 2004 Approval Of Triage For Ischemic, Hemorrhagic Stroke
Biosite expects its Triage Stroke protein test to be adjunctive to computed tomography in diagnosing ischemic and hemorrhagic stroke in hospital and physician lab settings
Biosite Aims For 2004 Approval Of Triage For Ischemic, Hemorrhagic Stroke
Biosite expects its Triage Stroke protein test to be adjunctive to computed tomography in diagnosing ischemic and hemorrhagic stroke in hospital and physician lab settings
Abbott AxSYM U.S. Presence May Give Firm Edge Over BNP Competitors
Abbott will try to leverage its installed U.S. base of 5,000 AxSYM automated analyzers to gain a competitive advantage over Bayer Diagnostics as each firm prepares a 2003 launch of a B-type natriuretic peptide (BNP) test to help diagnose congestive heart failure